Peptidylarginine deiminases: Physiological function, interaction with chemokines and role in pathology

Drug Discovery Today: Technologies

Volumn 9, Issue 4, 2012, Pages

  Moelants, Eva A V ^a   Mortier, Anneleen ^a   Van Damme, Jo ^a   Proost, Paul ^a   Loos, Tamara ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DEIMINASE 4; CD11B ANTIGEN; CHEMOKINE; CITRULLINE; CXCL11 CHEMOKINE; DIMETHYLARGININASE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOSAMINOGLYCAN; INTERLEUKIN 8; PACLITAXEL; PEPTIDYLCITRULLINE; PROTEIN ARGININE DEIMINASE; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CITRULLINATION; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME REGULATION; ENZYME SPECIFICITY; EPIDERMIS; EPIGENETICS; GENE CONTROL; GENETIC LINKAGE; GENETIC TRANSCRIPTION; GLAUCOMA; HAIR FOLLICLE; HAIR GROWTH; HOMEOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NONHUMAN; PATHOPHYSIOLOGY; PRION DISEASE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN UNFOLDING; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; TARGET CELL; TISSUE DISTRIBUTION;

EID: 84873090537     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.06.002     Document Type: Review

References (217)

1. Murphy, P.M. et al. (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176
2. Zlotnik, A. and Yoshie, O. (2000) Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127
3. Rot, A. and von Andrian, U.H. (2004) Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891-928
4. Strieter, R.M. et al. (2005) CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 16, 593-609
5. Mortier, A. et al. (2008) Regulation of chemokine activity by posttranslational modification. Pharmacol. Ther. 120, 197-217
6. Mortier, A. et al. (2010) Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp. Cell Res. 317, 642-654
7. Wolf, M. et al. (2008) Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int. J. Biochem. Cell Biol. 40, 1185-1198
8. Ludwig, A. and Weber, C. (2007) Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb. Haemost. 97, 694-703
9. Loos, T. et al. (2009) Chapter 1. Isolation, identification, and production of posttranslationally modified chemokines. Methods Enzymol. 461, 3-29
10. Loos, T. et al. (2008) Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 112, 2648-2656
11. Proost, P. et al. (2008) Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J. Exp. Med. 205, 2085-2097
12. Senshu, T. et al. (1996) Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem. Biophys. Res. Commun. 225, 712-719
13. Harding, C.R. and Scott, I.R. (1983) Histidine-rich proteins (filaggrins): structural and functional heterogeneity during epidermal differentiation. J. Mol. Biol. 170, 651-673
14. Tarcsa, E. et al. (1996) Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin. J. Biol. Chem. 271, 30709-30716
15. Nakashima, K. et al. (2002) Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J. Biol. Chem. 277, 49562-49568
16. Hagiwara, T. et al. (2005) Deimination of histone H2A and H4 at arginine 3 in HL-60 granulocytes. Biochemistry 44, 5827-5834
17. Hagiwara, T. et al. (2002) Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem. Biophys. Res. Commun. 290, 979-983
18. Li, P. et al. (2008) Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol. Cell Biol. 28, 4745-4758
19. Yao, H. et al. (2008) Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J. Biol. Chem. 283, 20060-20068
20. Struyf, S. et al. (2009) Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J. Immunol. 182, 666-674
21. Loos, T. et al. (2009) Citrullination of CXCL8 increases this chemokine's ability to mobilize neutrophils into the blood circulation. Haematologica 94, 1346-1353
22. Mortier, A. et al. (2010) Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine deiminases (PAD) differently affects its biological activity. J. Biol. Chem. 285, 29750-29759
23. Li, P. et al. (2010) PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207, 1853-1862
24. Wang, Y. et al. (2009) Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184, 205-213
25. Mastronardi, F.G. et al. (2006) Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J. Neurosci. 26, 11387-11396
26. Ishigami, A. et al. (2005) Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J. Neurosci. Res. 80, 120-128
27. Bhattacharya, S.K. et al. (2006) Proteomics implicates peptidyl arginine deiminase 2 and optic nerve citrullination in glaucoma pathogenesis. Invest Ophthalmol. Vis. Sci. 47, 2508-2514
28. Jang, B. et al. (2010) Involvement of peptidylarginine deiminasemediated post-translational citrullination in pathogenesis of sporadic Creutzfeldt-Jakob disease. Acta Neuropathol. 119, 199-210
29. Chang, X. and Fang, K. (2010) PADI4 and tumourigenesis. Cancer Cell Int. 10, 7
30. Lundberg, K. et al. (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 7, R458-R467
31. Curis, E. et al. (2005) Almost all about citrulline in mammals. Amino Acids 29, 177-205
32. Mori, M. (2007) Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J. Nutr. 137, 1616S-1620S
33. Fearon, W.R. (1939) The carbamido diacetyl reaction: a test for citrulline. Biochem. J. 33, 902-907
34. Young, E.G. and Smith, D.G. (1958) Amino acids, peptides, and proteins of Irish Moss, Chondrus crispus. J. Biol. Chem. 233, 406-410
35. Rogers, G.E. (1962) Occurrence of citrulline in proteins. Nature 194, 1149-1151
36. Rogers, G.E. and Taylor, L.D. (1977) The enzymic derivation of citrulline residues from arginine residues in situ during the biosynthesis of hair proteins that are cross-linked by isopeptide bonds. Adv. Exp. Med. Biol. 86A, 283-294
37. Fujisaki, M. and Sugawara, K. (1981) Properties of peptidylarginine deiminase from the epidermis of newborn rats. J. Biochem. 89, 257-263
38. Nomura, K. (1992) Specificity and mode of action of the muscle-type protein-arginine deiminase. Arch. Biochem. Biophys. 293, 362-369
39. Darrah, E. et al. (2011) Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann. Rheum. Dis. 71, 92-98
40. Nakayama-Hamada, M. et al. (2005) Comparison of enzymatic properties between hPADI2 and hPADI4. Biochem. Biophys. Res. Commun. 327, 192-200
41. Vossenaar, E.R. et al. (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25, 1106-1118
42. McGraw, W.T. et al. (1999) Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect. Immun. 67, 3248-3256
43. Touz, M.C. et al. (2008) Arginine deiminase has multiple regulatory roles in the biology of Giardia lamblia. J. Cell Sci. 121, 2930-2938
44. Guerrin, M. et al. (2003) cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type I. Biochem. J. 370, 167-174
45. Chavanas, S. et al. (2006) Peptidylarginine deiminases and deimination in biology and pathology: relevance to skin homeostasis. J. Dermatol. Sci. 44, 63-72
46. Chavanas, S. et al. (2004) Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved noncoding segments and a new human gene, PADI6. Gene 330, 19-27
47. Ishigami, A. et al. (2002) Human peptidylarginine deiminase type II: molecular cloning, gene organization, and expression in human skin. Arch. Biochem. Biophys. 407, 25-31
48. Balandraud, N. et al. (2005) A rigorous method for multigenic families' functional annotation: the peptidyl arginine deiminase (PADs) proteins family example. BMC Genomics 6, 153
49. Watanabe, K. et al. (1988) Combined biochemical and immunochemical comparison of peptidylarginine deiminases present in various tissues. Biochim. Biophys. Acta 966, 375-383
50. Watanabe, K. and Senshu, T. (1989) Isolation and characterization of cDNA clones encoding rat skeletal muscle peptidylarginine deiminase. J. Biol. Chem. 264, 15255-15260
51. Kanno, T. et al. (2000) Human peptidylarginine deiminase type III: molecular cloning and nucleotide sequence of the cDNA, properties of the recombinant enzyme, and immunohistochemical localization in human skin. J. Invest. Dermatol. 115, 813-823
52. Yamakoshi, A. et al. (1998) Cloning of cDNA encoding a novel isoform (type IV) of peptidylarginine deiminase from rat epidermis. Biochim. Biophys. Acta 1386, 227-232
53. Ishigami, A. et al. (1998) Molecular cloning of two novel types of peptidylarginine deiminase cDNAs from retinoic acid-treated culture of a newborn rat keratinocyte cell line. FEBS Lett. 433, 113-118
54. Asaga, H. et al. (2001) Immunocytochemical localization of peptidylarginine deiminase in human eosinophils and neutrophils. J. Leukoc. Biol. 70, 46-51
55. Nakashima, K. et al. (1999) Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3). J. Biol. Chem. 274, 27786-27792
56. Zhang, J. et al. (2004) cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type VI. Acta Biochim. Pol. 51, 1051-1058
57. Liu, M. et al. (2005) Peptidylarginine deiminase (PAD) is a mouse cortical granule protein that plays a role in preimplantation embryonic development. Reprod. Biol. Endocrinol. 3, 42
58. Jang, B. et al. (2011) Subcellular localization of peptidylarginine deiminase 2 and citrullinated proteins in brains of scrapie-infected mice: nuclear localization of PAD2 and membrane fraction-enriched citrullinated proteins. J. Neuropathol. Exp. Neurol. 70, 116-124
59. Dong, S. et al. (2008) Crucial roles of MZF1 and Sp1 in the transcriptional regulation of the peptidylarginine deiminase type I gene (PADI1) in human keratinocytes. J. Invest. Dermatol. 128, 549-557
60. Dong, S. et al. (2007) Estrogen-enhanced peptidylarginine deiminase type IV gene (PADI4) expression in MCF-7 cells is mediated by estrogen receptor-alpha-promoted transfactors activator protein-1, nuclear factor-Y, and Sp1. Mol. Endocrinol. 21, 1617-1629
61. Dong, S. et al. (2006) NF-Y and Sp1/Sp3 are involved in the transcriptional regulation of the peptidylarginine deiminase type III gene (PADI3) in human keratinocytes. Biochem. J. 397, 449-459
62. Dong, S. et al. (2005) Regulation of the expression of peptidylarginine deiminase type II gene (PADI2) in human keratinocytes involves Sp1 and Sp3 transcription factors. J. Invest. Dermatol. 124, 1026-1033
63. Cuthbert, G.L. et al. (2004) Histone deimination antagonizes arginine methylation. Cell 118, 545-553
64. Mastronardi, F.G. et al. (2007) Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J. Neurosci. Res. 85, 2006-2016
65. Lu, J. et al. (2005) Transcriptional profiling of keratinocytes reveals a vitamin D-regulated epidermal differentiation network. J. Invest. Dermatol. 124, 778-785
66. Andrade, F. et al. (2010) Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation. Arthritis Rheum. 62, 1630-1640
67. Mechin, M.C. et al. (2010) Deimination is regulated at multiple levels including auto-deimination of peptidylarginine deiminases. Cell Mol. Life Sci. 67, 1491-1503
68. Slack, J.L. et al. (2011) Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity. Biochemistry 50, 3997-4010
69. Liu, Y.L. et al. (2011) Functional role of dimerization of human peptidylarginine deiminase 4 (PAD4). PLoS ONE 6, e21314
70. Luo, Y. et al. (2006) A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J. Am. Chem. Soc. 128, 1092-1093
71. Pritzker, L.B. and Moscarello, M.A. (1998) A novel microtubule independent effect of paclitaxel: the inhibition of peptidylarginine deiminase from bovine brain. Biochim. Biophys. Acta 1388, 154-160
72. Stone, E.M. et al. (2005) Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase. Biochemistry 44, 13744-13752
73. Luo, Y. et al. (2006) Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry 45, 11727-11736
74. Willis, V.C. et al. (2011) N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)- Lornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J. Immunol. 186, 4396-4404
75. Chumanevich, A.A. et al. (2011) Suppression of colitis in mice by Clamidine: a novel peptidylarginine deiminase inhibitor. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G929-G938
76. Knuckley, B. et al. (2010) Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry 49, 4852-4863
77. Luo, Y. et al. (2006) Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe. J. Am. Chem. Soc. 128, 14468-14469
78. Knuckley, B. et al. (2008) Profiling protein arginine deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg. Med. Chem. 16, 739-745
79. Causey, C.P. et al. (2011) The development of N-alpha-(2-carboxyl) benzoyl-N(5)-(2-fluoro-1-iminoethyl)-L-ornithine amide (o-Famidine) and N-alpha-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-L-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors. J. Med. Chem. 54, 6919-6935
80. Jones, J.E. et al. (2012) Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem. Biol. 7, 160-165
81. Knuckley, B. et al. (2010) A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem. Commun. (Camb.) 46, 7175-7177
82. Takagi-Sato, M. et al. (2006) Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression. Nucleic Acids Symp. Ser. (Oxf.) 319-320
83. Takagi-Sato, M. et al. (2007) Fine-tuning of ENA gapmers as antisense oligonucleotides for sequence-specific inhibition. Oligonucleotides 17, 291-301
84. Yu, J.T. et al. (2009) Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog. Neurobiol. 89, 240-255
85. Rogers, G.E. (1963) The localization and significance of arginine and citrulline in proteins of the hair follicle. J. Histochem. Cytochem. 11, 700-705
86. Tarcsa, E. et al. (1997) The fate of trichohyalin. Sequential posttranslational modifications by peptidyl-arginine deiminase and transglutaminases. J. Biol. Chem. 272, 27893-27901
87. Nachat, R. et al. (2005) Peptidylarginine deiminase isoforms are differentially expressed in the anagen hair follicles and other human skin appendages. J. Invest. Dermatol. 125, 34-41
88. Rogers, G. et al. (1997) Peptidylarginine deiminase of the hair follicle: characterization, localization, and function in keratinizing tissues. J. Invest. Dermatol. 108, 700-707
89. Steinert, P.M. et al. (1998) Biochemical evidence that small proline-rich proteins and trichohyalin function in epithelia by modulation of the biomechanical properties of their cornified cell envelopes. J. Biol. Chem. 273, 11758-11769
90. Foulquier, C. et al. (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 56, 3541-3553
91. Mechin, M.C. et al. (2005) The peptidylarginine deiminases expressed in human epidermis differ in their substrate specificities and subcellular locations. Cell Mol. Life Sci. 62, 1984-1995
92. Kizawa, K. et al. (2008) Specific citrullination causes assembly of a globular S100A3 homotetramer: a putative Ca2+ modulator matures human hair cuticle. J. Biol. Chem. 283, 5004-5013
93. Wright, P.W. et al. (2003) ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets. Dev. Biol. 256, 73-88
94. Sugawara, K. et al. (1982) Identification and properties of peptidylarginine deiminase from rabbit skeletal muscle. J. Biochem. 91, 1065-1071
95. Khorasanizadeh, S. (2004) The nucleosome: from genomic organization to genomic regulation. Cell 116, 259-272
96. Saiki, M. et al. (2009) Recognition of the N-terminal histone H2A and H3 peptides by peptidylarginine deiminase IV. Protein Pept. Lett. 16, 1012-1016
97. Wang, Y. et al. (2004) Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306, 279-283
98. Hidaka, Y. et al. (2005) Methylation of the guanidino group of arginine residues prevents citrullination by peptidylarginine deiminase IV. FEBS Lett. 579, 4088-4092
99. Balint, B.L. et al. (2005) Arginine methylation provides epigenetic transcription memory for retinoid-induced differentiation in myeloid cells. Mol. Cell Biol. 25, 5648-5663
100. Shimoyama, S. et al. (2010) Deimination stabilizes histone H2A/H2B dimers as revealed by electrospray ionization mass spectrometry. J. Mass Spectrom. 45, 900-908
101. Lee, Y.H. et al. (2005) Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination. Proc. Natl. Acad. Sci. U. S. A. 102, 3611-3616
102. Raijmakers, R. et al. (2007) Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J. Mol. Biol. 367, 1118-1129
103. Tanikawa, C. et al. (2009) Regulation of protein Citrullination through p53/PADI4 network in DNA damage response. Cancer Res. 69, 8761-8769
104. Guo, Q. et al. (2011) Discovery of peptidylarginine deiminase-4 substrates by protein array: antagonistic citrullination and methylation of human ribosomal protein S2. Mol. Biosyst. 7, 2286-2295
105. Guo, Q. and Fast, W. (2011) Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J. Biol. Chem. 286, 17069-17078
106. Rossi, D. and Zlotnik, A. (2000) The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242
107. Johnson, Z. et al. (2005) Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 16, 625-636
108. Mortier, A. et al. (2011) Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation. PLoS ONE 6, e23913
109. Moelants, E.A.V. et al. (2011) Detection and quantification of citrullinated chemokines. PLoS ONE 6, e28976
110. Scapini, P. et al. (2000) The neutrophil as a cellular source of chemokines. Immunol. Rev. 177, 195-203
111. Brinkmann, V. et al. (2004) Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535
112. Steinberg, B.E. and Grinstein, S. (2007) Unconventional roles of the NADPH oxidase: signaling, ion homeostasis, and cell death. Sci. STKE 379, pe11
113. Remijsen, Q. et al. (2011) Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ. 18, 581-588
114. Neeli, I. et al. (2008) Histone deimination as a response to inflammatory stimuli in neutrophils. J. Immunol. 180, 1895-1902
115. Kessenbrock, K. et al. (2009) Netting neutrophils in autoimmune smallvessel vasculitis. Nat. Med. 15, 623-625
116. Hakkim, A. et al. (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U. S. A. 107, 9813-9818
117. Ishida-Yamamoto, A. et al. (2000) Decreased deiminated keratin K1 in psoriatic hyperproliferative epidermis. J. Invest. Dermatol. 114, 701-705
118. Coudane, F. et al. (2011) Deimination and expression of peptidylarginine deiminases during cutaneous wound healing in mice. Eur. J. Dermatol. 21, 376-384
119. Jang, B. et al. (2008) Accumulation of citrullinated proteins by up-regulated peptidylarginine deiminase 2 in brains of scrapieinfected mice: a possible role in pathogenesis. Am. J. Pathol. 173, 1129-1142
120. Wood, D.D. and Moscarello, M.A. (1989) The isolation, characterization, and lipid-aggregating properties of a citrulline containing myelin basic protein. J. Biol. Chem. 264, 5121-5127
121. Moscarello, M.A. et al. (1994) Myelin in multiple sclerosis is developmentally immature. J. Clin. Invest. 94, 146-154
122. Wood, D.D. et al. (1996) Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann. Neurol. 40, 18-24
123. Pritzker, L.B. et al. (2000) Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 39, 5374-5381
124. Musse, A.A. et al. (2006) Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc. Natl. Acad. Sci. U. S. A. 103, 4422-4427
125. Pritzker, L.B. et al. (2000) Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase. Biochemistry 39, 5382-5388
126. Keilhoff, G. et al. (2008) Expression pattern of peptidylarginine deiminase in rat and human Schwann cells. Dev. Neurobiol. 68, 101-114
127. Wood, D.D. et al. (2008) Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Lab. Invest. 88, 354-364
128. De Keyser, J. et al. (1999) Peptidylarginine deiminase activity in postmortem white matter of patients with multiple sclerosis. Neurosci. Lett. 260, 74-76
129. Nicholas, A.P. et al. (2005) Expression of citrullinated proteins in murineexperimentalautoimmune encephalomyelitis. J. Comp. Neurol. 486, 254-266
130. Nicholas, A.P. et al. (2004) Increased citrullinated glial fibrillary acidic protein in secondary progressive multiple sclerosis. J. Comp. Neurol. 473, 128-136
131. Raijmakers, R. et al. (2006) Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J. Comp. Neurol. 498, 217-226
132. Inagaki, M. et al. (1989) Ca2+-dependent deimination-induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain. J. Biol. Chem. 264, 18119-18127
133. White, E. (1996) Life, death, and the pursuit of apoptosis. Genes Dev. 10, 1-15
134. Chang, X. et al. (2005) Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 44, 40-50
135. Liu, G.Y. et al. (2006) Overexpression of peptidylarginine deiminase IV features in apoptosis of haematopoietic cells. Apoptosis 11, 183-196
136. Slack, J.L. et al. (2011) Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol. Life Sci. 68, 709-720
137. Zendman, A.J. et al. (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford) 45, 20-25
138. Nijenhuis, S. et al. (2004) Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin. Chim. Acta 350, 17-34
139. Lee, D.M. and Weinblatt, M.E. (2001) Rheumatoid arthritis. Lancet 358, 903-911
140. Goldbach-Mansky, R. et al. (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2, 236-243
141. Renaudineau, Y. et al. (2005) Rheumatoid factor on a daily basis. Autoimmunity 38, 11-16
142. Paimela, L. et al. (1992) Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann. Rheum. Dis. 51, 743-746
143. Simon, M. et al. (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called antikeratin antibodies, autoantibodies specific for rheumatoid arthritis. J. Clin. Invest. 92, 1387-1393
144. Hoet, R.M. et al. (1991) Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann. Rheum. Dis. 50, 611-618
145. Sebbag, M. et al. (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 95, 2672-2679
146. Schellekens, G.A. et al. (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101, 273-281
147. Masson-Bessiere, C. et al. (2000) In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin. Exp. Immunol. 119, 544-552
148. Masson-Bessiere, C. et al. (2001) The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J. Immunol. 166, 4177-4184
149. Zhao, Y. et al. (2007) Prevalence and clinical significance of antibodies to citrullinated fibrinogen (ACF) in Chinese patients with rheumatoid arthritis. Clin. Rheumatol. 26, 1505-1512
150. Takizawa, Y. et al. (2006) Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann. Rheum. Dis. 65, 1013-1020
151. Ordonez, A. et al. (2009) Effect of citrullination on the function and conformation of antithrombin. FEBS J. 276, 6763-6772
152. Ordonez, A. et al. (2010) Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thromb. Haemost. 104, 1143-1149
153. Chang, X. et al. (2005) Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology (Oxford) 44, 1374-1382
154. Suzuki, A. et al. (2005) Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem. Biophys. Res. Commun. 333, 418-426
155. Burkhardt, H. et al. (2005) Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur. J. Immunol. 35, 1643-1652
156. Kinloch, A. et al. (2005) Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res. Ther. 7, R1421-R1429
157. Okazaki, Y. et al. (2006) Identification of citrullinated eukaryotic translation initiation factor 4G1 as novel autoantigen in rheumatoid arthritis. Biochem. Biophys. Res. Commun. 341, 94-100
158. Vossenaar, E.R. et al. (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res. Ther. 6, R142-R150
159. Menard, H.A. et al. (2000) Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res. 2, 429-432
160. Bang, H. et al. (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 56, 2503-2511
161. Matsuo, K. et al. (2006) Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res. Ther. 8, R175
162. Goeb, V. et al. (2009) Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res. Ther. 11, R38
163. Tabushi, Y. et al. (2008) Detection of citrullinated proteins in synovial fluids derived from patients with rheumatoid arthritis by proteomicsbased analysis. Ann. Clin. Biochem. 45, 413-417
164. Avouac, J. et al. (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 65, 845-851
165. Snir, O. et al. (2010) Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 62, 44-52
166. Roth, E.B. et al. (2006) Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis - new pathways to epitope spreading. Clin. Exp. Rheumatol. 24, 12-18
167. Takizawa, Y. et al. (2005) Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand. J. Rheumatol. 34, 212-215
168. Nissinen, R. et al. (2003) Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patientswith rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren syndrome. Scand. J. Rheumatol. 32, 337-342
169. Kolfenbach, J.R. et al. (2010) Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 62, 2633-2639
170. Zhao, J. et al. (2008) Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J. Rheumatol. 35, 969-974
171. Halvorsen, E.H. et al. (2008) Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann. Rheum. Dis. 67, 414-417
172. Auger, I. et al. (2010) Rheumatoid arthritis-specific autoantibodies to peptidyl arginine deiminase type 4 inhibit citrullination of fibrinogen. Arthritis Rheum. 62, 126-131
173. Pollmann, S. et al. (2012) Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate. Rheumatol. Int. 32, 1271-1276
174. Vossenaar, E.R. et al. (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 63, 373-381
175. De Rycke, L. et al. (2005) Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum. 52, 2323-2330
176. Kinloch, A. et al. (2008) Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum. 58, 2287-2295
177. Routsias, J.G. et al. (2011) Autopathogenic correlation of periodontitis and rheumatoid arthritis. Rheumatology (Oxford) 50, 1189-1193
178. Mangat, P. et al. (2010) Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis? Arthritis Res Ther. 12, 209
179. Gregersen, P.K. et al. (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213
180. Bridges, S.L., Jr et al. (2008) The HLA-DRB1 shared epitope in Caucasians with rheumatoid arthritis: a lesson learned from tic-tac-toe. Arthritis Rheum. 58, 1211-1215
181. Hill, J.A. et al. (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1&z.ast;0401 MHC class II molecule. J. Immunol. 171, 538-541
182. Hughes, L.B. et al. (2008) The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum. 58, 349-358
183. Shiozawa, S. et al. (1998) Identification of the gene loci that predispose to rheumatoid arthritis. Int. Immunol. 10, 1891-1895
184. Suzuki, A. et al. (2003) Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34, 395-402
185. Kang, C.P. et al. (2006) A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum. 54, 90-96
186. Gandjbakhch, F. et al. (2009) A functional haplotype of PADI4 gene in rheumatoid arthritis: positive correlation in a French population. J. Rheumatol. 36, 881-886
187. Hoppe, B. et al. (2006) Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study. Arthritis Res. Ther. 8, R34
188. Harney, S.M. et al. (2005) Genetic and genomic studies of PADI4 in rheumatoid arthritis. Rheumatology (Oxford) 44, 869-872
189. Poor, G. et al. (2007) Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1110, 23-32
190. Martinez, A. et al. (2005) PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. Rheumatology (Oxford) 44, 1263-1266
191. Caponi, L. et al. (2005) A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann. Rheum. Dis. 64, 587-593
192. Cantaert, T. et al. (2005) Functional haplotypes of PADI4: relevance for rheumatoid arthritis specific synovial intracellular citrullinated proteins and anticitrullinated protein antibodies. Ann. Rheum. Dis. 64, 1316-1320
193. Suzuki, M. et al. (2006) Evaluation of allele frequencies in the PADI4 gene and anti-cyclic citrullinated peptide antibodies of patients with rheumatoid arthritis in a Japanese population. Ann. Rheum. Dis. 65, 1399-1400
194. Plenge, R.M. et al. (2005) Replication of putative candidate-gene associations with rheumatoid arthritis in >4000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am. J. Hum. Genet. 77, 1044-1060
195. Ikari, K. et al. (2005) Association between PADI4 and rheumatoid arthritis: a replication study. Arthritis Rheum. 52, 3054-3057
196. Iwamoto, T. et al. (2006) Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford) 45, 804-807
197. Lee, Y.H. et al. (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol. Int. 27, 827-833
198. Hoppe, B. et al. (2009) Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann. Rheum. Dis. 68, 898-903
199. Cha, S. et al. (2007) Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis. Arthritis Rheum. 56, 1454-1463
200. Nishimoto, K. et al. (2008) Lack of association between PADI4 and functional severity in Japanese rheumatoid arthritis patients. Ann. Rheum. Dis. 67, 431-432
201. Harris, M.L. et al. (2008) Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum. 58, 1958-1967
202. Remmers, E.F. et al. (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357, 977-986
203. Zhu, J. et al. (2011) Single nucleotide polymorphisms at the TRAF1/C5 locus are associated with rheumatoid arthritis in a Han Chinese population. BMC Med. Genet. 12, 53
204. Moreno, O. et al. (2007) Polymorphisms in the IL4 and IL4RA genes in Colombian patients with rheumatoid arthritis. J. Rheumatol. 34, 36-42
205. Lundstrom, E. et al. (2009) Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum. 60, 1597-1603
206. Makrygiannakis, D. et al. (2008) Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann. Rheum. Dis. 67, 1488-1492
207. Kochi, Y. et al. (2011) PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. Ann. Rheum. Dis. 70, 512-515
208. Nachat, R. et al. (2005) Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. J. Invest. Dermatol. 124, 384-393
209. Urano, Y. et al. (1990) Immunohistochemical demonstration of peptidylarginine deiminase in human sweat glands. Am. J. Dermatopathol. 12, 249-255
210. Chang, X. et al. (2009) The expression of PADI4 in synovium of rheumatoid arthritis. Rheumatol. Int. 29, 1411-1416
211. Takahara, H. et al. (1983) Purification and characterization of peptidylarginine deiminase from rabbit skeletal muscle. J. Biochem. 94, 1945-1953
212. Pike, R.N. et al. (1997) Heparin-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity. J. Biol. Chem. 272, 19652-19655
213. Imparl, J.M. et al. (1995) Studies of calcineurin-calmodulin interaction: probing the role of arginine residues using peptidylarginine deiminase. Arch. Biochem. Biophys. 318, 370-377
214. Azuma, N. et al. (1991) Enzymic modification of alpha s1-casein with peptidylarginine deiminase: preparation of less acid-coagulable and less calcium-sensitive casein. J. Dairy Res. 58, 421-429
215. Skriner, K. et al. (2006) Association of citrullinated proteins with synovial exosomes. Arthritis Rheum. 54, 3809-3814
216. Van Steendam, K. et al. (2010) Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res. Ther. 12, R132
217. Luo, S. et al. (1995) Enzymatic deimination of glycogen phosphorylase and a peptide of the phosphorylation site: identification of modification and roles in phosphorylation and activity. Arch. Biochem. Biophys. 318, 362-369